These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 23958540)

  • 1. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
    Castro J; Harrington AM; Hughes PA; Martin CM; Ge P; Shea CM; Jin H; Jacobson S; Hannig G; Mann E; Cohen MB; MacDougall JE; Lavins BJ; Kurtz CB; Silos-Santiago I; Johnston JM; Currie MG; Blackshaw LA; Brierley SM
    Gastroenterology; 2013 Dec; 145(6):1334-46.e1-11. PubMed ID: 23958540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.
    Eutamene H; Bradesi S; Larauche M; Theodorou V; Beaufrand C; Ohning G; Fioramonti J; Cohen M; Bryant AP; Kurtz C; Currie MG; Mayer EA; Bueno L
    Neurogastroenterol Motil; 2010 Mar; 22(3):312-e84. PubMed ID: 19706070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.
    Rao SS; Quigley EM; Shiff SJ; Lavins BJ; Kurtz CB; MacDougall JE; Currie MG; Johnston JM
    Clin Gastroenterol Hepatol; 2014 Apr; 12(4):616-23. PubMed ID: 24075889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
    Busby RW; Bryant AP; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Mahajan-Miklos S; Pierce CM; Solinga RM; Sun LJ; Tobin JV; Kurtz CB; Currie MG
    Eur J Pharmacol; 2010 Dec; 649(1-3):328-35. PubMed ID: 20863829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.
    Bryant AP; Busby RW; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Pierce CM; Solinga RM; Tobin JV; Mahajan-Miklos S; Cohen MB; Kurtz CB; Currie MG
    Life Sci; 2010 May; 86(19-20):760-5. PubMed ID: 20307554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation.
    Silos-Santiago I; Hannig G; Eutamene H; Ustinova EE; Bernier SG; Ge P; Graul C; Jacobson S; Jin H; Liong E; Kessler MM; Reza T; Rivers S; Shea C; Tchernychev B; Bryant AP; Kurtz CB; Bueno L; Pezzone MA; Currie MG
    Pain; 2013 Sep; 154(9):1820-1830. PubMed ID: 23748116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM; Shiff SJ; Quigley EM
    Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
    Quigley EM; Tack J; Chey WD; Rao SS; Fortea J; Falques M; Diaz C; Shiff SJ; Currie MG; Johnston JM
    Aliment Pharmacol Ther; 2013 Jan; 37(1):49-61. PubMed ID: 23116208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges of managing pain in constipation-predominant IBS: clinical perspectives on antinociceptive actions of linaclotide.
    Hasler WL; Owyang C
    Gastroenterology; 2013 Dec; 145(6):1196-9. PubMed ID: 24409483
    [No Abstract]   [Full Text] [Related]  

  • 11. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
    Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
    J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux.
    Tchernychev B; Ge P; Kessler MM; Solinga RM; Wachtel D; Tobin JV; Thomas SR; Lunte CE; Fretzen A; Hannig G; Bryant AP; Kurtz CB; Currie MG; Silos-Santiago I
    J Pharmacol Exp Ther; 2015 Oct; 355(1):48-56. PubMed ID: 26216942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction.
    Grundy L; Harrington AM; Castro J; Garcia-Caraballo S; Deiteren A; Maddern J; Rychkov GY; Ge P; Peters S; Feil R; Miller P; Ghetti A; Hannig G; Kurtz CB; Silos-Santiago I; Brierley SM
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity
    Boulete IM; Thadi A; Beaufrand C; Patwa V; Joshi A; Foss JA; Eddy EP; Eutamene H; Palejwala VA; Theodorou V; Shailubhai K
    World J Gastroenterol; 2018 May; 24(17):1888-1900. PubMed ID: 29740204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.
    Johnston JM; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; O'Dea C; Baird M; Lembo AJ
    Gastroenterology; 2010 Dec; 139(6):1877-1886.e2. PubMed ID: 20801122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of linaclotide for patients with chronic constipation.
    Lembo AJ; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; Jeglinski BI; Johnston JM
    Gastroenterology; 2010 Mar; 138(3):886-95.e1. PubMed ID: 20045700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
    Videlock EJ; Cheng V; Cremonini F
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1084-1092.e3; quiz e68. PubMed ID: 23644388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome.
    Sedky AA; Magdy Y
    Life Sci; 2020 Sep; 256():117960. PubMed ID: 32534033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological and clinical profile of linaclotide (Linzess
    Keto Y; Kosako M
    Nihon Yakurigaku Zasshi; 2019; 153(6):289-298. PubMed ID: 31178535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.